XZB-0004 is under clinical development by SignalChem Lifesciences and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XZB-0004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XZB-0004 overview

SLC-391 is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), squamous non-small cell lung cancer, metastatic transitional (urothelial) tract cancer, metastatic melanoma, acute myelocytic leukemia (AML), colorectal cancer, coronavirus disease (COVID-19), relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome. The drug candidate is a small molecule that acts by targeting AXL kinase. It is developed based on the KineCore technology. It is administered through oral route. The drug candidate was also under development for colon carcinoma and ovarian cancer.
 SLC-391 was under development for the treatment of chronic myelocytic leukemia (CML), ovarian cancer, colon carcinoma.

SignalChem Lifesciences overview

SignalChem Lifesciences (SLC) is a biotechnology company that discovers and develops novel therapies for oncology. The company is investigating SLC-391, an orally bioavailable small molecule AXL inhibitors to treat acute myelogenous leukemia and non-small cell lung cancer; and SLC-0111, a carbonic anhydrase IX (CAIX) Inhibitor targeting pancreatic cancer. It is also evaluating additional programs targeting cancer and SARS-CoV-2 (corona virus). SLC provides drug discovery, in-vitro diagnostic development, research and development solutions. The company works in collaboration with pharmaceutical and biopharmaceutical companies to develop its products. SLC is headquartered in Richmond, British Columbia, Canada.

For a complete picture of XZB-0004’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.